Literature DB >> 20300760

[Osteoarthritis in hereditary metabolic diseases].

J Zwerina1, T Dallos.   

Abstract

Primary osteoarthritis (OA) of peripheral joints is a common disease mainly occurring after the age of 50. It is important to distinguish primary from secondary OA. Younger age at disease onset, rapid progression, unusual disease manifestations and co-morbidities are signs of secondary OA. This review outlines an important group of secondary OA. Hereditary metabolic diseases can exhibit joint involvement. For some of these diseases, correct diagnosis is critical, since appropriate therapy influences not only joint function and quality of life, but can also prevent relevant end-organ damage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20300760     DOI: 10.1007/s00393-009-0590-8

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  47 in total

1.  Radiological features of the visceral and skeletal involvement of hemochromatosis.

Authors:  H J Jäger; U Mehring; G F Götz; M Neise; R Erlemann; H J Kapp; K D Mathias
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

2.  HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis.

Authors:  C Mura; O Raguenes; C Férec
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

3.  Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA.

Authors:  Ernest Beutler; Vincent J Felitti; James A Koziol; Ngoc J Ho; Terri Gelbart
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

4.  Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls.

Authors:  P Holmström; J Marmur; G Eggertsen; M Gåfvels; P Stål
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

5.  Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis.

Authors:  C Niederau; R Fischer; A Sonnenberg; W Stremmel; H J Trampisch; G Strohmeyer
Journal:  N Engl J Med       Date:  1985-11-14       Impact factor: 91.245

6.  Chondrocalcinosis and arthropathy: studies in haemochromatosis and in idiopathic chondrocalcinosis.

Authors:  C J Atkins; J McIvor; P M Smith; E Hamilton; R Williams
Journal:  Q J Med       Date:  1970-01

7.  Increased mortality risk in patients with phenotypic hereditary hemochromatosis but not in their first-degree relatives.

Authors:  Maria Elmberg; Rolf Hultcrantz; Fereshte Ebrahim; Sigvard Olsson; Stefan Lindgren; Lars Lööf; Per Stål; Sven Wallerstedt; Sven Almer; Hanna Sandberg-Gertzén; Anders Ekbom; Johan Askling
Journal:  Gastroenterology       Date:  2009-07-18       Impact factor: 22.682

Review 8.  Non-HFE haemochromatosis.

Authors:  Daniel-F Wallace; V-Nathan Subramaniam
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

9.  Transplantation of a liver with the C282Y mutation into a recipient heterozygous for H63D results in iron overload.

Authors:  Mohammad K Ismail; Antonio Martinez-Hernandez; Steven Schichman; Sufiyan Chaudhry; Bradford Waters
Journal:  Am J Med Sci       Date:  2009-02       Impact factor: 2.378

10.  HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity.

Authors:  Lyle C Gurrin; Nadine A Bertalli; Gregory W Dalton; Nicholas J Osborne; Clare C Constantine; Christine E McLaren; Dallas R English; Dorota M Gertig; Martin B Delatycki; Amanda J Nicoll; Melissa C Southey; John L Hopper; Graham G Giles; Gregory J Anderson; John K Olynyk; Lawrie W Powell; Katrina J Allen
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

View more
  1 in total

1.  Ultrasound verified inflammation and structural damage in patients with hereditary haemochromatosis-related arthropathy.

Authors:  Christian Dejaco; Andreas Stadlmayr; Christina Duftner; Viktoria Trimmel; Rusmir Husic; Elisabeth Krones; Shahin Zandieh; Emma Husar-Memmer; Gernot Zollner; Josef Hermann; Judith Gretler; Angelika Lackner; Anja Ficjan; Christian Datz; Roland Axman; Jochen Zwerina
Journal:  Arthritis Res Ther       Date:  2017-10-24       Impact factor: 5.156

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.